{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:41:25Z","timestamp":1792453285628,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41391-019-0189-3","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T12:02:19Z","timestamp":1575028939000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Risk of dementia following androgen deprivation therapy for treatment of prostate cancer"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-308X","authenticated-orcid":false,"given":"Anna","family":"Krasnova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbra A.","family":"Dickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-8529","authenticated-orcid":false,"given":"Alexander P.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart R.","family":"Lipsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzad","family":"Basaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorelei A.","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"189_CR1","unstructured":"American Cancer Society. Facts & figures 2019. Atlanta, GA: American Cancer Society; 2019."},{"key":"189_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms Version 3 [Internet]. National Comprehensive Cancer Network. 2018. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"189_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.beem.2013.05.001","volume":"27","author":"M Grossmann","year":"2013","unstructured":"Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pr Res Clin Endocrinol Metab [Internet]. 2013;27:603\u201316. Available from: https:\/\/doi.org\/10.1016\/j.beem.2013.05.001","journal-title":"Best Pr Res Clin Endocrinol Metab [Internet]"},{"key":"189_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ecl.2011.05.004","volume":"40","author":"M Grossmann","year":"2011","unstructured":"Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am. 2011;40:655\u201371.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"189_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.juro.2017.11.136","volume":"199","author":"M Sun","year":"2018","unstructured":"Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199:1417\u201325.","journal-title":"J Urol."},{"key":"189_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1200\/JCO.2015.63.6266","volume":"34","author":"KT Nead","year":"2016","unstructured":"Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al. Androgen deprivation therapy and future Alzheimer\u2019s disease risk. J Clin Oncol. 2016;34:566\u201371.","journal-title":"J Clin Oncol"},{"key":"189_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/pcan.2017.10","volume":"20","author":"KT Nead","year":"2017","unstructured":"Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis [Internet]. 2017;20:259\u201364. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28349979","journal-title":"Prostate Cancer Prostatic Dis [Internet]"},{"key":"189_CR8","doi-asserted-by":"publisher","first-page":"e196562","DOI":"10.1001\/jamanetworkopen.2019.6562","volume":"2","author":"R Jayadevappa","year":"2019","unstructured":"Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancerandrogen deprivation therapy and dementia diagnosis in men with prostate cancerandrogen deprivation therapy and dementia diagnosis in men with prosta. JAMA Netw Open [Internet]. 2019;2:e196562\u2013e196562. Available from: https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6562","journal-title":"JAMA Netw Open [Internet]"},{"key":"189_CR9","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2017.72.6109","volume":"35","author":"SH Baik","year":"2017","unstructured":"Baik SH, Kury FSP, McDonald CJ. Risk of Alzheimer\u2019s disease among senior medicare beneficiaries treated with androgen deprivation therapy for prostate cancer. J Clin Oncol. 2017;35:3401\u20139.","journal-title":"J Clin Oncol"},{"key":"189_CR10","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/j.ijrobp.2018.07.396","volume":"102","author":"R Deka","year":"2018","unstructured":"Deka R, Rose BS, Bryant AK, Sarkar RR, Nalawade V, Mckay R, et al. ADT and depression in veterans with prostate cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys [Internet]. 2018;102:e106\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618318509","journal-title":"Int J Radiat Oncol Biol Phys [Internet]"},{"key":"189_CR11","unstructured":"National Cancer Institute. SEER*Stat Databases: November 2017 Submission: Incidence\u2013SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2017 Sub (2000\u20132015) [Internet]. Available from: https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2017\/"},{"key":"189_CR12","first-page":"IV-3","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care [Internet]. 2002;40(8 Suppl):IV-3\u201318. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12187163","journal-title":"Med Care [Internet]"},{"key":"189_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.urolonc.2014.05.005","volume":"32","author":"P Ravi","year":"2014","unstructured":"Ravi P, Karakiewicz PI, Roghmann F, Gandaglia G, Choueiri TK, Menon M, et al. Mental health outcomes in elderly men with prostate cancer1Equal contribution. Urol Oncol Semin Orig Investig [Internet]. 2014;32:1333\u201340. Available from: https:\/\/doi.org\/10.1016\/j.urolonc.2014.05.005","journal-title":"Urol Oncol Semin Orig Investig [Internet]"},{"key":"189_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc [Internet]. 1999;94:496. Available from: http:\/\/www.jstor.org\/stable\/2670170","journal-title":"J Am Stat Assoc [Internet]"},{"key":"189_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol [Internet]. 1992;45:613\u20139. Available from: http:\/\/www.jclinepi.com\/article\/0895-4356(92)90133-8\/pdf","journal-title":"J Clin Epidemiol [Internet]"},{"key":"189_CR16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med [Internet]. 2014;33:1242\u201358. Available from: http:\/\/doi.wiley.com\/10.1002\/sim.5984","journal-title":"Stat Med [Internet]"},{"key":"189_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ctrv.2017.09.010","volume":"61","author":"A Matsos","year":"2017","unstructured":"Matsos A, Loomes M, Zhou I, Macmillan E, Sabel I, Rotziokos E, et al. Chemotherapy-induced cognitive impairments: White matter pathologies. Cancer Treat Rev [Internet]. 2017;61:6\u201314. Available from: https:\/\/doi.org\/10.1016\/j.ctrv.2017.09.010","journal-title":"Cancer Treat Rev [Internet]"},{"key":"189_CR18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1073\/pnas.032646799","volume":"99","author":"SC Papasozomenos","year":"2002","unstructured":"Papasozomenos SC, Shanavas A. Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer\u2019s disease. Proc Natl Acad Sci USA [Internet]. 2002;99:1140\u20135. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=122157&tool=pmcentrez&rendertype=abstract","journal-title":"Proc Natl Acad Sci USA [Internet]"},{"key":"189_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3233\/JAD-2008-15304","volume":"15","author":"SC Papasozomenos","year":"2008","unstructured":"Papasozomenos SC, Papasozomenos H. The activation of heat shock transcription factor 1 is differentially regulated in the brain of estrogen- and testosterone-treated heat-shocked rats. J Alzheimers Dis [Internet]. 2008;15:375\u201390. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18997291","journal-title":"J Alzheimers Dis [Internet]"},{"key":"189_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0304-3940(03)00898-X","volume":"350","author":"H Kanemitsu","year":"2003","unstructured":"Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett [Internet]. 2003;350:113\u20136. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12972166","journal-title":"Neurosci Lett [Internet]"},{"key":"189_CR21","doi-asserted-by":"publisher","first-page":"7326","DOI":"10.1523\/JNEUROSCI.1180-10.2010","volume":"30","author":"C McAllister","year":"2010","unstructured":"McAllister C, Long J, Bowers A, Walker A, Cao P, Honda S-I, et al. Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment. J Neurosci [Internet]. 2010;30:7326\u201334. Available from: https:\/\/doi.org\/10.1523\/JNEUROSCI.1180-10.2010","journal-title":"J Neurosci [Internet]"},{"key":"189_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0006-8993(00)03155-3","volume":"892","author":"E Ahlbom","year":"2001","unstructured":"Ahlbom E, Prins GS, Ceccatelli S. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res [Internet]. 2001;892:255\u201362. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11172772","journal-title":"Brain Res [Internet]"},{"key":"189_CR23","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1046\/j.1471-4159.2001.00345.x","volume":"77","author":"J Hammond","year":"2001","unstructured":"Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem [Internet]. 2001;77:1319\u201326. Available from: https:\/\/doi.org\/10.1046\/j.1471-4159.2001.00345.x","journal-title":"J Neurochem [Internet]"},{"key":"189_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.annepidem.2014.06.099","volume":"24","author":"N Chawla","year":"2014","unstructured":"Chawla N, Yabroff KR, Mariotto A, McNeel TS, Schrag D, Warren JL. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. Ann Epidemiol [Internet]. 2014;24:666\u2013.e2. Available from: https:\/\/doi.org\/10.1016\/j.annepidem.2014.06.099","journal-title":"Ann Epidemiol [Internet]"},{"key":"189_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/jgs.15638","volume":"67","author":"CW Zhu","year":"2019","unstructured":"Zhu CW, Ornstein KA, Cosentino S, Gu Y, Andrews H, Stern Y. Misidentification of dementia in medicare claims and related costs. J Am Geriatr Soc [Internet]. 2019;67:269\u201376. Available from: https:\/\/doi.org\/10.1111\/jgs.15638","journal-title":"J Am Geriatr Soc [Internet]"},{"key":"189_CR26","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1200\/JCO.2016.66.6594","volume":"34","author":"JJ Leow","year":"2016","unstructured":"Leow JJ, Cole AP, Sun M, Trinh Q-D. Association of androgen deprivation therapy with alzheimer\u2019s disease: unmeasured confounders. J Clin Oncol [Internet]. 2016;34:2801\u20133. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27298418","journal-title":"J Clin Oncol [Internet]"},{"key":"189_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol [Internet]. 2016;79:70\u20135. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435616301366","journal-title":"J Clin Epidemiol [Internet]"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0189-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0189-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0189-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:29Z","timestamp":1684618469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-019-0189-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["189"],"URL":"https:\/\/doi.org\/10.1038\/s41391-019-0189-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"3 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Toni K. Choueiri reports institutional and personal research support from AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi\/Aventis, Takeda. Toni K. Choueiri reports honoraria from AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, Bristol Myers-Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics, Lilly. Toni K. Choueiri reports consulting or advisory role with AstraZeneca, Alexion, Sanofi\/Aventis, Bayer, Bristol Myers-Squibb\/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Lilly, Ipsen, Up-to-Date, NCCN, Analysis Group. Toni K. Choueiri reports no speaker\u2019s bureau, no leadership or employment in for-profit companies. Other present or past leadership roles of Toni K. Choueiri: Director of GU Oncology Division at Dana-Farber and past President of medical Staff at Dana-Farber, member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee. Additionally, Toni K. Choueiri reports no patents, royalties or other intellectual properties. He reports travel, accommodations, expenses, in relation to consulting, advisory roles, or honoraria. His medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies. Furthermore, the institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter. Adam S. Kibel reports honoraria from profound, InSightec, Janssen, Merck, Pfizer, Blue Earth Diagnostics. Quoc-Dien Trinh is supported by the Brigham Research Institute Fund to Sustain Research Excellence, the Bruce A. Beal and Robert L. Beal Surgical Fellowship, the Genentech Bio-Oncology Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology, a Health Services Research pilot test grant from the Defense Health Agency, the Clay Hamlin Young Investigator Award from the Prostate Cancer Foundation and an unrestricted educational grant from the Vattikuti Urology Institute. All remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}